Mirum Pharmaceuticals, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Q3 2026 net product sales totaled $185.7M (vs. $133.0M YoY), with LIVMARLI at $133.4M (+45% YoY) and Bile Acid Medicines at $52.3M (+28% YoY). Full-year 2026 net product sales guidance raised to $715–720M. Mirum received FDA approval and launched ATEBRIOZ (zilurgisertib) for FOP; reported positive Phase 3 results for LIVMARLI EXPAND (biliary atresia), brelovitug AZURE-1 (HDV), and ATEBRIOZ PROGRESS (pediatric FOP); received Orphan Drug Designation for brelovitug in HDV. Pipeline includes five planned regulatory submissions/label expansions in 2026–2027. Cash, cash equivalents, and investments stood at $500.5M (vs. $391.4M Dec 2025); Q3 operating loss was $59.7M on operating expenses of $245.5M (vs. $130.4M YoY).
Why this rating
Strong revenue growth (+40% YoY) and raised guidance represent meaningful commercial momentum; multiple near-term pipeline approvals/expansions provide growth catalysts. At ~$2.3B market cap, $715–720M annual revenue run-rate is material; cash position adequate. Offset by rising R&D spend and near-term losses.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.